Cerevance will present Phase 2 data for Solengepras at the American Academy of Neurology 2026 Annual Meeting in Chicago, held April 18 to 22. The company reports that Solengepras, a once-daily oral non-dopaminergic GPR6 inhibitor, demonstrated meaningful reductions in daily OFF time and improvements in sleep-related symptoms across two Phase 2 trials.
Two poster presentations on April 21 at 11:45 a.m. CT will be presented by Robert Hauser, M.D., M.B.A., and Harini Sarva, M.D. Solengepras (CVN424) is being evaluated as an adjunct to levodopa in the ongoing randomized, double-blind, placebo-controlled Phase 3 ARISE trial, which plans to enroll approximately 330 patients aged 30 and older with motor fluctuations and an average of 3 or more hours of total OFF time per day.
Participants are randomized to Solengepras 75 mg, 150 mg or placebo once daily for 12 weeks; the primary endpoint is the change from baseline to week 12 in average daily OFF time for the 150 mg dose versus placebo.
ARISE is being conducted at sites in the United States, Europe and Australia. The company claims Solengepras aims to restore motor and non-motor function without directly affecting dopamine signaling.
